Rapport Therapeutics reported total assets of $458.98M and total liabilities of $36.06M for the quarter ended Jun 2026, up 60.8% year over year. This balance sheet covers 13 quarters of results from Jun 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accumulated Depreciation | 0.13M | 0.48M | 0.70M | 0.96M | 1.21M | 1.46M | 1.72M | 1.98M | 1.93M | 2.14M | |||
| Assets | |||||||||||||
| Current Assets | |||||||||||||
| Cash & EquivalentsCash & Equiv. | 79.53M | 159.41M | 70.17M | 74.27M | 110.16M | 39.31M | 56.80M | 57.60M | 55.07M | 513.00M | 52.65M | 476.80M | 63.61M |
| Receivables - NetNet Receivables | 0.06M | 0.30M | |||||||||||
| Receivables | 0.06M | 0.30M | |||||||||||
| Prepaid Assets | 3.31M | 4.42M | 5.17M | 4.42M | 5.48M | 9.69M | 7.53M | 7.92M | 7.75M | 10.38M | |||
| Current Assets | 150.87M | 340.67M | 325.94M | 309.80M | 290.97M | 270.24M | 520.66M | 498.56M | 484.69M | 446.86M | |||
| Non-Current Assets | |||||||||||||
| Property, Plant & Equipment (Net) | 1.92M | 3.47M | 3.41M | 3.53M | 3.40M | 3.17M | 3.12M | 2.98M | 2.52M | 2.34M | |||
| Other Non-Current Assets | 0.55M | 0.19M | 0.19M | 0.16M | 0.21M | 1.03M | 1.07M | 0.98M | 1.06M | 1.06M | |||
| Non-Current Assets | 4.55M | 5.43M | 5.21M | 5.13M | 11.09M | 15.25M | 14.66M | 13.87M | 12.90M | 12.13M | |||
| Assets | 155.42M | 346.10M | 331.14M | 314.93M | 302.05M | 285.50M | 535.32M | 512.43M | 497.60M | 458.98M | |||
| Liabilities | |||||||||||||
| Current Liabilities | |||||||||||||
| Accounts Payables | 2.50M | 1.88M | 1.32M | 1.95M | 2.14M | 3.18M | 3.23M | 4.19M | 6.56M | 2.80M | |||
| Payables | 2.50M | 1.88M | 1.32M | 1.95M | 2.14M | 3.18M | 3.23M | 4.19M | 6.56M | 2.80M | |||
| Accumulated Expenses | 5.63M | 5.52M | 5.06M | 6.08M | 6.24M | 6.94M | 8.60M | 12.10M | 8.72M | 23.16M | |||
| Other Accumulated Expenses | 0.11M | 0.37M | 0.28M | 0.47M | 0.32M | 0.07M | 0.10M | 0.01M | 0.14M | 0.22M | |||
| Current Leases | 0.67M | 0.70M | 0.72M | 0.74M | 1.01M | 1.76M | 2.48M | 2.75M | 2.62M | 2.47M | |||
| Total Current Liabilities | 8.80M | 8.10M | 7.10M | 8.77M | 9.38M | 11.88M | 14.32M | 19.05M | 17.90M | 28.42M | |||
| Non-Current Liabilities | |||||||||||||
| Preferred Stock Liabilities | 89.49M | 89.49M | 166.58M | 145.25M | |||||||||
| Operating Leases | 1.48M | 1.12M | 0.93M | 0.74M | 6.83M | 10.10M | 9.39M | 8.73M | 8.19M | 7.63M | |||
| Other Non-Current Liabilities | 4.20M | 9.43M | |||||||||||
| Total Non-Current Liabilities | 10.28M | 0.07M | |||||||||||
| Total Liabilities | 9.43M | 13.12M | 14.48M | 39.63M | 9.21M | 8.03M | 9.51M | 16.22M | 21.98M | 23.71M | 27.78M | 26.09M | 36.06M |
| Shareholder's Equity | |||||||||||||
| Common Equity | -9.43M | -13.12M | -25.63M | -39.63M | 336.89M | 323.11M | 305.43M | 285.84M | 263.51M | 511.62M | 484.65M | 471.51M | 422.93M |
| Liabilities and Shareholders Equity | 155.42M | 346.10M | 331.14M | 314.93M | 302.05M | 285.50M | 535.32M | 512.43M | 497.60M | 458.98M | |||
| Treasury Shares | 100.18M | 100.18M | 151.46M | 189.61M | |||||||||
| Retained Earnings | -45.44M | -86.23M | -103.80M | -123.75M | -147.81M | -174.54M | -201.50M | -235.23M | -255.10M | -311.70M |